Peptides As Therapeutics with Enhanced Bioactivity
The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Abstract
The development of techniques for efficient peptide production renewed interest in peptides as therapeutics. Numerous modifications for improving stability, transport and affinity profiles now exist. Several new adjuvant and carrier systems have also been developed, enhancing the immunogenicity of peptides thus allowing their development as vaccines. This review describes the established and experimental approaches for manufacturing peptide drugs and highlights the techniques currently used for improving their drug like properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,647 · cited 14×
“Two chemical methodologiessolution-phase (SPS), and solid-phase peptide synthesis (SPPS) [4] - are the predominant methods of chemical synthesis, but many other approaches, including hybrid synthesis and chemoselective ligation, have also been studied.”
MethodInfluentialSynthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476 · cited 1×
“Other approaches included the use of other unnatural residues, modification of peptide bonds, termini protection/modifications and conjugation to carrier constructs, such as biocompatible polymers [72].”
BackgroundActivation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349 · cited 2×
“enhanced stability over the unmodified BID BH3 peptide in mouse serum [142].”
BackgroundZuckermann, R. N., Kerr, J. M., Kent, S. B. H., & Moos, W. H. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00052a076 · Cited by 1,277 · cited 1×
“Zuckermann and colleagues introduced a family of peptidomimetics called ‘peptoids’ [114].”
BackgroundTam, J. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5409 · Cited by 1,251 · cited 2×
“Unlike some other formulations, peptide-based subunit vaccines exist as one entity inclusive of all components essential for a successful vaccine, incorporating adjuvant, carrier and antigen [46, 47].”
BackgroundFood-derived peptides with biological activity: from research to food applications.
Hartmann, R., & Meisel, H. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.01.013 · Cited by 1,102 · cited 1×
“Peptides were derived from bovine milk proteins that had angiotensin converting enzyme inhibitory, immunomodulatory, antithrombotic and hypocholesterolemic activities [36-38].”
MethodContemporary strategies for peptide macrocyclization
White, C. J., & Yudin, A. K. (2011) · Nature Chemistry · doi:10.1038/nchem.1062 · Cited by 1,088 · cited 1×
“Since the 1940s, the interest in cyclic peptides has grown substantially [134].”
BackgroundSCHNölzer, M., ALEWOOD, P., JONES, A., ALEWOOD, D., & KENT, S. B. H. (1992) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1992.tb00291.x · Cited by 1,049
Seebach, D., Overhand, M., Kühnle, F. N. M., Martinoni, B., Oberer, L., Hommel, U., & Widmer, H. (1996) · Helvetica Chimica Acta · doi:10.1002/hlca.19960790402 · Cited by 734 · cited 1×
“-Peptidomimetics also assumed defined helical structures, with as few as six residues able to form a helix [121].”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 2×
“2 to 13 hours after subcutaneous administration [41].”
Background
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
“lactamization, lactonization, and sulfide-based bridges (4).”
BackgroundMultifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action
Akbarian, M., Khani, A., Eghbalpour, S., & Uversky, V. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031445 · Cited by 612
“glycoprotein CSF114, which are used for infectious diseases and the clinical diagnosis of multiple sclerosis, respectively [42].”
Background
Metadata
- Authors
- Goodwin, D., Simerska, P., & Toth, I.
- Affiliations
- The University of Queensland (AU)
- ORCID
- Goodwin, D.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 19
- Issue
- 26
- Pages
- 4451-4461
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2162532167
- Cited by
- 176
- References
- 142
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 15 · 2021: 20 · 2020: 14 · 2019: 14 · 2018: 19 · 2017: 17 · 2016: 16 · 2015: 9 · 2014: 14 · 2013: 8
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- U.S. Food and Drug Administration
- Australian Research Council
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- peptide therapeutics, peptide synthesis, peptide stability, bioavailability, drug delivery, peptide vaccine, adjuvants, immunogenicity, peptide modification, clinical trials
- MeSH terms
- Amino Acid Sequence, Animals, Humans, Peptides, Vaccines, Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptides As Therapeutics with Enhanced Bioactivity. https://app.cochat.ai/papers/10.2174/092986712803251548
- The paper
- Goodwin, D., Simerska, P., & Toth, I. (2012). Peptides As Therapeutics with Enhanced Bioactivity. Current Medicinal Chemistry. https://doi.org/10.2174/092986712803251548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.